Comparison
Why is Pliant Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-235.26%
EBIT to Interest (avg)
-105.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.39
EV to EBIT
0.74
EV to EBITDA
0.75
EV to Capital Employed
10.02
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1348.03%
ROE (Latest)
-85.36%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Movement
8What is working for the Company
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
OPERATING PROFIT(Q)
Highest at USD -45.14 MM
PRE-TAX PROFIT(Q)
Highest at USD -43.3 MM
NET PROFIT(Q)
Highest at USD -43.3 MM
EPS(Q)
Highest at USD -0.71
-8What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -169.39 MM
INTEREST(9M)
At USD 2.44 MM has Grown at 49.45%
ROCE(HY)
Lowest at -67.55%
DEBT-EQUITY RATIO
(HY)
Highest at -92.01 %
Here's what is working for Pliant Therapeutics, Inc.
Operating Profit
Highest at USD -45.14 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -43.3 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -43.3 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.71
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Pliant Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -169.39 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Interest
At USD 2.44 MM has Grown at 49.45%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at -92.01 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio






